Cyclophosphamide
Lung Adenocarcinoma
Anusha KalbasiSmall moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
63 Active assets in the Lung Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Guangdong Association of Clinical Trials | Phase 3 | BBB |
Etoposide Guangdong Association of Clinical Trials | Phase 3 | BB |
Cis-Diamminedichloroplatinum Ii Guangdong Association of Clinical Trials | Phase 3 | BB |
Nivolumab Emory University | Phase 3 | BB |
Docetaxel Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →